2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02469896 (ClinicalTrials.gov) | November 2015 | 3/6/2015 | A Trial of Tocilizumab in ALS Subjects | A Phase 2 Randomized, Placebo Controlled Trial of Tocilizumab in ALS Subjects | ALS;Amyotrophic Lateral Sclerosis;Lou Gehrig's Disease;Motor Neuron Disease | Drug: Tocilizumab;Other: Placebo | Barrow Neurological Institute | ALS Association;Barrow Neurological Foundation;Massachusetts General Hospital;Genentech, Inc. | Completed | 18 Years | 75 Years | All | 22 | Phase 2 | United States |